BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,735,240 | -39.3% | 436,833 | -27.2% | 0.00% | -40.0% |
| Q2 2023 | $49,005,101 | -6.7% | 600,332 | -15.2% | 0.01% | -16.7% |
| Q1 2023 | $52,513,553 | -27.5% | 707,825 | -19.0% | 0.01% | -25.0% |
| Q4 2022 | $72,452,508 | +47.8% | 874,186 | +406.3% | 0.01% | +33.3% |
| Q3 2022 | $49,034,000 | -24.3% | 172,658 | -7.5% | 0.01% | -14.3% |
| Q2 2022 | $64,737,000 | -18.0% | 186,756 | +2.4% | 0.01% | -12.5% |
| Q1 2022 | $78,955,000 | +7.3% | 182,327 | +28.1% | 0.01% | +14.3% |
| Q4 2021 | $73,610,000 | +75.1% | 142,287 | +64.0% | 0.01% | +75.0% |
| Q3 2021 | $42,044,000 | +14.8% | 86,765 | +6.7% | 0.00% | 0.0% |
| Q2 2021 | $36,625,000 | +20.2% | 81,340 | +2.0% | 0.00% | +33.3% |
| Q1 2021 | $30,459,000 | -5.4% | 79,750 | -21.4% | 0.00% | -25.0% |
| Q4 2020 | $32,201,000 | +14.3% | 101,406 | -10.9% | 0.00% | 0.0% |
| Q3 2020 | $28,178,000 | +0.1% | 113,751 | +6.7% | 0.00% | 0.0% |
| Q2 2020 | $28,163,000 | +23.8% | 106,652 | -11.1% | 0.00% | 0.0% |
| Q1 2020 | $22,742,000 | -17.7% | 119,928 | -4.7% | 0.00% | 0.0% |
| Q4 2019 | $27,631,000 | +7.4% | 125,877 | -4.2% | 0.00% | 0.0% |
| Q3 2019 | $25,720,000 | +5.4% | 131,449 | +12.3% | 0.00% | 0.0% |
| Q2 2019 | $24,410,000 | -17.4% | 117,083 | -21.3% | 0.00% | -20.0% |
| Q1 2019 | $29,540,000 | +94.2% | 148,778 | +41.5% | 0.01% | +66.7% |
| Q4 2018 | $15,211,000 | -62.1% | 105,109 | -46.5% | 0.00% | -50.0% |
| Q3 2018 | $40,128,000 | +27.2% | 196,600 | -7.8% | 0.01% | +20.0% |
| Q2 2018 | $31,539,000 | -14.2% | 213,167 | -12.5% | 0.01% | -16.7% |
| Q1 2018 | $36,780,000 | +8.2% | 243,514 | -7.2% | 0.01% | 0.0% |
| Q4 2017 | $33,982,000 | -25.1% | 262,312 | -30.1% | 0.01% | -14.3% |
| Q3 2017 | $45,379,000 | +46.9% | 375,375 | +42.8% | 0.01% | +16.7% |
| Q2 2017 | $30,897,000 | +21.9% | 262,952 | +5.4% | 0.01% | +20.0% |
| Q1 2017 | $25,353,000 | +21.1% | 249,413 | +22.5% | 0.01% | 0.0% |
| Q4 2016 | $20,932,000 | +7.0% | 203,561 | +14.0% | 0.01% | +25.0% |
| Q3 2016 | $19,554,000 | -8.7% | 178,573 | -5.9% | 0.00% | -20.0% |
| Q2 2016 | $21,406,000 | -3.9% | 189,822 | -19.5% | 0.01% | 0.0% |
| Q1 2016 | $22,278,000 | +8.1% | 235,687 | +2.9% | 0.01% | 0.0% |
| Q4 2015 | $20,618,000 | -0.8% | 229,090 | +1.9% | 0.01% | 0.0% |
| Q3 2015 | $20,783,000 | +3943.4% | 224,765 | +4200.9% | 0.01% | – |
| Q2 2015 | $514,000 | -10.9% | 5,226 | -9.2% | 0.00% | – |
| Q1 2015 | $577,000 | +145.5% | 5,753 | +126.5% | 0.00% | – |
| Q4 2014 | $235,000 | – | 2,540 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
| Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
| Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
| Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
| DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
| Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
| Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
| STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
| Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
| Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |